Ot­su­ka sub­sidiary gets date with FDA for Lon­surf com­bo; Vax­cyte sells stock to bankroll PhI­II vac­cine tri­al

Ot­su­ka sub­sidiary Tai­ho On­col­o­gy an­nounced Tues­day morn­ing that the FDA has ac­cept­ed its ap­pli­ca­tion for a com­bo in­di­ca­tion for Lon­surf, which is cur­rent­ly ap­proved for third- or fourth-line metasta­t­ic col­orec­tal can­cer.

With pri­or­i­ty re­view, the FDA has un­til Aug. 13 to de­cide on whether or not to ap­prove Tai­ho’s drug in com­bi­na­tion with Roche’s Avastin in the same lines of treat­ment that Lon­surf is al­ready avail­able as a monother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER